ETN-101

N/A

Report date: 2025/06/05 16:57:37

Base Information

Drug NameETN-101

Drug Alias NameETN101ETN-101MBP-11901

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionTyrosine-protein kinase receptor FLT3 inhibitorsStem cell growth factor receptor inhibitorsPlatelet-derived growth factor receptor beta inhibitors +[4]

TargetsTyrosine-protein kinase receptor FLT3Stem cell growth factor receptorPlatelet-derived growth factor receptor beta +[4]

Therapy Area/IndicationsLiver NeoplasmsCarcinoma, Hepatocellular

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesEtnova Therapeutics Corp

China Registration ClassN/A

Develop Information

Active CompaniesEtnova Therapeutics Corp

Inactive CompaniesN/A

Active IndicationsLiver NeoplasmsCarcinoma, Hepatocellular

Inactive IndicationsN/A

Other Information

ATC CodeN/A